Olmesartan-associated enteropathy a review of clinical and histologic findings

Archives of Pathology and Laboratory Medicine

Volumn 139, Issue 10, 2015, Pages 1242-1247

  Choi, Eun Young Karen ^a   McKenna, Barbara J ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHYPERTENSIVE AGENT; IMIDAZOLE DERIVATIVE; OLMESARTAN; TETRAZOLE DERIVATIVE;

CELIAC DISEASE; CHEMICALLY INDUCED; DIARRHEA; DIFFERENTIAL DIAGNOSIS; DRUG EFFECTS; GASTROINTESTINAL TRACT; HUMAN; INTESTINAL DISEASES; PATHOLOGY; POLYENDOCRINOPATHIES, AUTOIMMUNE; TREATMENT WITHDRAWAL;

ANTIHYPERTENSIVE AGENTS; CELIAC DISEASE; DIAGNOSIS, DIFFERENTIAL; DIARRHEA; GASTROINTESTINAL TRACT; HUMANS; IMIDAZOLES; INTESTINAL DISEASES; POLYENDOCRINOPATHIES, AUTOIMMUNE; TETRAZOLES; WITHHOLDING TREATMENT;

EID: 84942891036     PISSN: 00039985     EISSN: 15432165     Source Type: Journal    
DOI: 10.5858/arpa.2015-0204-RA     Document Type: Article

References (31)

1. FDA Drug Safety Communication. FDA approves label changes to include intestinal problems (sprue-like enteropathy) linked to blood pressure medicine olmesartan medoxomil. US Food and Drug Administration Web site. http: //www. fda. gov/Drugs/DrugSafety/ucm359477. htm. Accessed April 27, 2015.
2. Chobanian AV, Bakris GL, Black HR, et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension. 2003; 42(6): 1206-1252.
3. Rubio-Tapia A, Herman ML, Ludvigsson JF, et al. Severe spruelike enteropathy associated with olmesartan. Mayo Clin Proc. 2012; 87(8): 732-738.
4. Abdelghany M, Gonzalez L III, Slater J, Begley C. Olmesartan associated sprue-like enteropathy and colon perforation. Case Rep Gastrointest Med. 2014; 2014: 494098. doi: 10. 1155/2014/494098.
5. Bhat N, Anupama NK, Yelsangikar A, Vizhi K. Olmesartan-related spruelike enteropathy. Indian J Gastroenterol. 2014; 33(6): 564-567.
6. DeGaetani M, Tennyson CA, Lebwohl B et al. Villous atrophy and negative celiac serology: A diagnostic and therapeutic dilemma. Am J Gastroenterol. 2013; 108(5): 647-653.
7. Dreifuss SE, Tomizawa Y, Farber NJ, Davison JM, Sohnen AE. Spruelike enteropathy associated with olmesartan: An unusual case of severe diarrhea. Case Rep Gastrointest Med. 2013; 2013: 618071. doi: 10. 1155/2013/618071
8. Gallivan C, Brown I. Olmesartan induced enterocolitis. Pathology. 2014; 46(4): 360-361.
9. Heerasing N, Hair C, Wallace S. Olmesartan-induced enteropathy. Intern Med J. 2015; 45(1): 117-118.
10. Ianiro G, Bibbo S, Montalto M, Ricci R, Gasbarrini A, Cammarota G. Systematic review: sprue-like enteropathy associated with olmesartan. Aliment Pharmacol Ther. 2014; 40(1): 16-23.
11. Marthey L, Cadiot G, Seksik P, et al. Olmesartan-associated enteropathy: results of a national survey. Aliment Pharmacol Ther. 2014; 40(9): 1103-1109.
12. Nielsen JA, Steephen A, Lewin M. Angiotensin-II inhibitor (olmesartan)-induced collagenous sprue with resolution following discontinuation of drug. World J Gastroenterol. 2013; 19(40): 6928-6930.
13. Stanich PP, Yearsley M, Meyer MM. Olmesartan-associated sprue-like enteropathy. J Clin Gastroenterol. 2013; 47(10): 894-895.
14. Theophile H, David XR, Miremont-Salame G, Haramburu F. Five cases of sprue-like enteropathy in patients treated by olmesartan. Dig Liver Dis. 2014; 46(5): 465-469.
15. Tran TH, Li H. Olmesartan and drug-induced enteropathy. P T. 2014; 39(1): 47-50.
16. deFonseka A, Tuskey A, Moskaluk C. A case of olmesartan induced enteropathy. Inflamm Bowel Dis. 2012; 18(suppl 1): S17.
17. Gaur V, Albeldawi M, Weber L. Chronic diarrhea and weight loss. Gastroenterology. 2014; 146(2): 591.
18. Marietta EV, Cartee A, Rishi A, Murray JA. Drug-induced enteropathy. Dig Dis. 2015; 33(2): 215-220.
19. Fiorucci G, Puxeddu E, Colella R, Paolo Reboldi G, Villanacci V, Bassotti G. Severe spruelike enteropathy due to olmesartan. Rev Esp Enferm Dig. 2014; 106(2): 142-144.
20. Khan AS, Peter S, Wilcox CM. Olmesartan-induced enteropathy resembling celiac disease. Endoscopy. 2014; 46(suppl 1): E97-E98.
21. Lagana SM, Braunstein ED, Arguelles-Grande C, Bhagat G, Green PH, Lebwohl B. Sprue-like histology in patients with abdominal pain taking olmesartan compared with other angiotensin receptor blockers. J Clin Pathol. 2015; 68(1): 29-32.
22. Menne J, Haller H. Olmesartan and intestinal adverse effects in the ROADMAP study. Mayo Clin Proc. 2012; 87(12): 1230-1232.
23. Greywoode R, Braunstein ED, Arguelles-Grande C, Green PH, Lebwohl B. Olmesartan, other antihypertensives, and chronic diarrhea among patients undergoing endoscopic procedures: A case-control study. Mayo Clin Proc. 2014; 89(9): 1239-1243.
24. Cyrany J, Vasatko T, Machac J, Nova M, Szanyi J, Kopacova M. Letter: Telmisartan-associated enteropathy-is there any class effect? Aliment Pharmacol Ther. 2014; 40(5): 569-570.
25. Herman ML, Rubio-Tapia A, Marietta E, Wu TT, Murray JA. Severe enteropathy in a patient on valsartan. Am J Gastroenterol. 2013; 108(suppl 1): S302.
26. Maier H, Hehemann K, Vieth M. Celiac disease-like enteropathy due to antihypertensive therapy with the angiotensin-II receptor type 1 inhibitor eprosartan. Cesk Patol. 2015; 51(2): 87-88.
27. Akram S, Murray JA, Pardi DS, et al. Adult autoimmune enteropathy: Mayo Clinic Rochester experience. Clin Gastroenterol Hepatol. 2007; 5(11): 1282-1290.
28. Pai RK. A practical approach to small bowel biopsy interpretation: celiac disease and its mimics. Semin Diagn Pathol. 2014; 31(2): 124-136.
29. Freeman HJ. Adult celiac disease and the severe ''flat'' small bowel biopsy lesion. Dig Dis Sci. 2004; 49(4): 535-545.
30. Washington K, Jagasia M. Pathology of graft-versus-host disease in the gastrointestinal tract. Hum Pathol. 2009; 40(7): 909-917.
31. Greenson JK. The biopsy pathology of non-coeliac enteropathy. Histopathology. 2015; 66(1): 29-36.